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Abstract: As the adult population is increasing, prostate cancer (PCa) will become a   considerable 
health problem in the next millennium. This has raised public interest in potential chemopreven-
tion of this disease. As PCa is extremely common and generally slow to progress it is regarded as 
an ideal candidate for chemoprevention. At present, the 5 alpha-reductase inhibitors finasteride 
and dutasteride have been identified as preventive agents. This review describes whether sele-
nium, alpha-tocopherol, isoflavones, lycopene green tea polyphenols, calcium, and resveratrol 
may be useful for decreasing the risk of PCa in men. Although encouraging results are present, 
some studies show negative results. Differences in study design, sample size, dose administered, 
and/or concentrations achieved in the body may be the reason for these inconsistencies. Today, 
chemopreventive agents may be appropriate for high-risk patients like those with high-grade 
prostatic intraepithelial neoplasia and other high-risk groups such as patients with elevated 
prostate specific antigen (PSA) and negative biopsy, rapid PSA velocity, and with a family 
history of PCa. Although larger randomized controlled studies are needed and epidemiologic 
evidence should be placed in a clinical context, physicians must be aware of these preven-
tive opportunities in PCa care. Combinations of chemopreventive agents should be carefully 
  investigated because mechanisms of action may be additive or synergistic.
Keywords: alpha-tocopherol, chemoprevention, isoflavones, lycopene, polyphenols, prostate 
cancer, selenium
Introduction
The incidence and mortality of prostate cancer (PCa) shows strong variations worldwide 
with the highest rates in North America, Australia, Western and Northern Europe and 
the lowest rates in Japan and other Asian countries. Interestingly, however, the incidence 
of latent or clinical PCa in autopsy studies among men from Japan and the US is not 
substantially different. A diversity of genetic and environmental factors play a role in 
the development of PCa. In the last years, the risk for PCa has dramatically increased 
in Japan, possibly due to the introduction of the western diet. Moreover, migrant studies 
have shown an increase in PCa incidence in Asian men after   emigration to the United 
States.1,2 These men adopt a western lifestyle with a high-fat, high-protein, low-fiber 
diet that lacks certain substances of the Asian diet such as plant-derived antioxidants, 
isoflavone-containing soy, and tea polyphenols that may protect against the development 
of cancer.3,4 Therefore, it is hypothesized that dietary changes and pharmacologic 
intervention could have an impact on PCa development and progression.5 Prostate 
cancer is an ideal target disease for chemoprevention because it is a very heterogeneous 
disease with a large subgroup of patients with nonaggressive disease. The situation Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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has become critical with the rapid implementation of early 
  detection tools, especially prostate specific antigen (PSA), 
so that most cancers are diagnosed years before they may 
become clinically evident and life-threatening for the 
patients. This poses a huge burden on the healthcare sys-
tem because of the costs associated with its diagnosis and 
therapy. Therefore, even a moderate reduction or delay in the 
development of PCa accomplished through pharmacologic 
or dietary intervention could result in a considerable reduc-
tion in the incidence of PCa. PCa will become progressively 
important in patients over the age of 50 with increasing life 
expectancy in the next millennium. This suggests that PCa 
will become an even more considerable health problem and 
emphasizes the importance of preventive strategies. Chemo-
prevention is defined as the use of specific natural (dietary) 
or synthetic agents to prevent, delay, or slow the carcinogenic 
process. Primary chemoprevention should be a nontoxic and 
cost-effective intervention in a population of individuals at 
sufficiently increased risk. The simplest way for primary 
chemoprevention is the application of dietary nutrients or 
supplements in an easily available form, as most men prefer 
to take a tablet rather than to change their dietary habits.
Significant research has been carried out in chemopre-
vention for PCa over the past 2 years. Several randomized 
studies for prevention of PCa with pharmaceutical agents, 
dietary changes, and supplements have been published. The 
5 alpha-reductase inhibitors finasteride and dutasteride have 
been identified as preventive agents and are discussed in 
many reviews. In the present review, we describe some of 
the more promising dietary nutrients and supplements and 
summarize the clinical studies on their effect on PCa, based 
on a review of the literature.
Potential prostate cancer  
preventive agents
Selenium and vitamin e
Selenium is an essential trace element found in vegetables, 
grains, red meat, fish, poultry, and eggs. The concentration 
of selenium in the vegetables depends on how much of the 
mineral was in the soil where the plants grew. Selenium is 
distributed in body tissues and helps to make special proteins, 
called antioxidant enzymes, which play a role in preventing 
cell damage. Epidemiologic evidence provides support for 
a global cancer prevention effect. Vitamin E is an essential 
lipid-soluble antioxidant found in plant oils such as soy, 
corn, and olive oil. Other sources include nuts, seeds, and 
green leafy vegetables. It protects cells from free radicals. 
Several forms of vitamin E have been identified. The most 
active form with highest bioavailability in human tissues is 
alpha-tocopherol. The body is not capable of producing this 
substance, and it must be consumed in the diet or   supplements 
for proper health.
The rationale for the use of selenium as a chemopre-
ventive agent comes from the Nutritional Prevention of 
Cancer (NPC) Trial. On secondary analysis, this random-
ized, double-blind, placebo-controlled skin cancer preven-
tion trial showed that it significantly reduced the overall 
incidence of PCa with a relative risk (RR) of 0.51 (95% 
confidence interval [CI]: 0.29–0.87). The protective effect 
of selenium supplementation (200 µg daily) was restricted 
to those with lower baseline PSA (#4 ng/mL) (RR: 0.35, 
95% CI: 0.13–0.87), although the interaction of baseline PSA 
and treatment was not statistically significant. Participants 
with baseline plasma selenium concentrations only in the 
lowest two tertiles (,123.2 ng/mL) had significant reduc-
tions in prostate cancer incidence. The unadjusted estimate 
showed a significant 65% reduction in PCa incidence with 
selenium supplementation.6 The rationale for the use of alpha-
tocopherol as chemopreventive agent for PCa was based on 
the Alpha-Tocopherol, Beta-carotene Cancer Prevention 
(ATBC) study.7 On secondary analysis, the ATBC lung 
cancer prevention trial found a statistically significant 32% 
reduction in PCa incidence (95% CI: 12–47, P = 0.002) in 
those receiving alpha-tocopherol (50 mg/day). The reduction 
was evident in clinical PCa but not in latent cancer. In addi-
tion, a 41% reduction in PCa mortality (95% CI: 1%–65%) 
was observed among men in the alpha-tocopherol group from 
1985 to 1993.8 An additional follow-up of 12 years showed 
that higher serum alpha-tocopherol at baseline was associ-
ated with improved PCa survival (Hazard ratio [HR]: 0.67, 
95% CI: 0.45–1.00). The strongest survival relationship was 
seen for those who received alpha-tocopherol supplementa-
tion and were in the highest serum alpha-tocopherol quin-
tile at baseline (HR: 0.51, 95% CI: 0.20–0.90) or at 3-year 
follow-up measurement (HR: 0.26, 95% CI: 0.09–0.71). 
Neither serum nor supplemental   beta-carotene or serum 
retinol had apparent effects on survival.9 These positive 
findings for alpha-tocopherol in the ATBC trial stand in 
contrast to those recently reported by the Physicians’ Health 
Study II (PHS II) trial which evaluated much higher dosages 
of alpha-tocopherol for shorter periods.
Based on the indirect evidences, selenium and vitamin E 
were tested separately and in combination for the preven-
tion of PCa in a randomized, prospective, double-blind, 
Phase III study, known as the Selenium and Vitamin E Cancer 
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  largest cancer prevention study ever performed. It randomized 
35,533 men to four groups: selenium (200 µg/day) +   placebo; 
vitamin E (400 IU/day) + placebo; selenium +   vitamin E; or 
placebo + placebo. Eligibility criteria were age 50 years or 
older for African-Americans, 55 years or older for Cauca-
sians, a serum PSA level of 4 ng/mL or less, a digital rectal 
examination not suspicious for cancer, and normal blood 
pressure. The primary endpoint was biopsy-confirmed PCa. 
No statistically significant differences in the rates of PCa were 
observed among the four groups. The HR was 1.13 (99% 
CI: 0.95–1.35) in the vitamin E-alone group, 1.04 (99% CI: 
0.87–1.24) in the selenium-alone group and 1.05 (99% CI: 
0.88–1.25) in the selenium with vitamin E group, compared 
with placebo. The study was terminated at 7 years (planned 
duration was 12 years) because no effect on the risk of PCa in 
these relatively healthy men could be demonstrated by neither 
selenium nor vitamin E or in combination at the doses and 
formulations used in the study.10 Concerns of the SELECT 
trial were a modest increase in the risk of PCa with vitamin E 
(P = 0.06) and in the risk of type 2 diabetes in the selenium 
group (RR: 1.07, 95% CI: 0.94–1.22, P = 0.16).10
Reasons why selenium and/or vitamin E, alone or in 
combination, failed to prevent PCa in the SELECT trial 
are not clear. First, the high dose of vitamin E (400 IU/D 
of the alpha-tocopherol form) in SELECT may have been 
less effective than a lower dose such as the 8-fold lower 
50 mg/d (roughly equivalent to 50 IU/D) that produced the 
earlier positive secondary findings in the ATBC study.10 
At a relatively high dose, natural vitamin E did not reduce 
PCa incidence. Achieving higher plasma or tissue levels 
of alpha-tocopherol within the physiologic range, such as 
through a 50 mg/d supplement, may have some prostate 
cancer (or other) preventive effect such as cell proliferation 
or tumor growth inhibition. This would also explain why 
in the PHS II study that enrolled 14,641 physicians aged 
50 years or older including 1307 men with a history of prior 
cancer at randomization, no effect of high dose vitamin E 
(400 IU every other day; HR: 0.97, 95% CI: 0.85–1.13) and 
similarly no effect of vitamin C (500 mg/day) (HR: 1.02, 
95% CI: 0.90–1.15) were found on PCa incidence during 
the 8 years follow-up.11 Second, several studies have 
suggested that vitamin E is more protective against PCa in 
smokers, and less than 60% of SELECT men were current 
or former smokers, whereas in the ATBC study all men were 
smokers. The fact that selenium was ineffective in preventing 
PCa could be due to the type of selenium used. In SELECT, 
200 µg of L-selenomethionine was chosen whereas in the 
NPC trial, the 200 µg of high-selenium yeast contained only 
20% of L-selenomethionine.6,10 Therefore, future investiga-
tions are necessary to point out if selenium yeast is a better 
choice in the prevention of PCa. An alternative explanation 
is the existence of a genetic susceptibility to the effect of 
selenium.
For example, Chan et al have assessed manganese super-
oxide dismutase (SOD2) gene variants and plasma selenium 
in 489 patients with localized/locally advanced prostate 
cancer. SOD2 is an endogenous mitochondrial enzyme that 
metabolizes reactive oxygen species and superoxide anions 
to oxygen and hydrogen peroxide. Several polymorphisms 
of SOD2 have been identified, including, a single nucle-
otide permutation that encodes either an alanine (A) or a 
valine (V). SOD2 genotype alone was not associated with 
disease aggressiveness, whereas higher versus lower selenium 
levels were associated with a slightly increased likelihood 
of presenting with aggressive disease (RR: 1.35; 95% CI: 
0.99–1.84). There was evidence of an interaction between 
SOD2 and selenium levels such that among men with the 
AA genotype, higher selenium levels were associated with a 
reduced risk of presenting with aggressive disease (RR: 0.60; 
95% CI: 0.32–1.12), whereas among men with a V allele, 
higher selenium levels were associated with an increased risk 
of aggressive disease (for VV or VA men, RR: 1.82; 95% CI: 
1.27–2.61; P for interaction , 0.007).12
Finally, it may be hypothesized that the positive effects 
of selenium in the NPC study and the positive effects of 
vitamin E on PCa incidence in the ATBC trial could have 
been due to chance in secondary analyses. In addition, 
recently published results from the Prostate Cancer Preven-
tion Trial found no significant association between vitamin E 
and selenium and the incidence of PCa.13 Moreover, long-
term supplemental intake of vitamin E ($400 IU/day) in the 
VITamins And Lifestyle (VITAL) study was not associated 
with PCa risk overall; however, the risk of clinically rel-
evant advanced disease was reduced with greater long-term 
(10-year average intake) vitamin E supplementation.14 
Currently, several prevention studies are ongoing or have 
been completed. A Canadian randomized Phase III trial is 
investigating the effect of combining vitamin E, selenium, 
and soy protein in preventing PCa in 306 patients who have 
high-grade prostatic intraepithelial neoplasia (HGPIN) 
(ClinicalTrials.gov Identifier NCT00064194). HGPIN is 
generally considered as a precursor of PCa. Prevention of 
PCa is desirable and men with HGPIN would be suitable, 
high-risk patients. A randomized, double-blind, placebo-
controlled, Phase III trial   (Southwest Oncology Group pro-
tocol 9917) funded by a National   Cancer Institute program Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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supporting pivotal   prevention trials is ongoing to evaluate 
the   effectiveness of selenium alone in preventing PCa in 
approximately 450 patients aged 40 years or older who have 
HGPIN and PSA levels of #10 ng/mL (ClinicalTrials.gov 
Identifier NCT00030901).15 Initial results were presented at 
the Annual Meeting of the American Urological Association 
in 2010. On average, 1.7 cores were involved with PIN on the 
first biopsy and 0.9 cores on the second biopsy.   Treatment 
compliance was good with 80% of patients still taking the 
drug at the end of 3 years but 35% of patients were not acces-
sible for the primary endpoint due to not getting the final 
prostate biopsy on time, or at all. At the time of this analysis, 
50 patients on selenium and 50 patients on placebo had PCa. 
The tumors were mostly Gleason score 2–6 with no differ-
ence between groups. The author concluded that 200 mg of 
selenium does not prevent PCa in men with HGPIN.16
Further research is required to determine the choice of 
selenium type, before it can be recommended in the pre-
vention of PCA. Caution is necessary when recommending 
high doses of selenium and/or vitamin E for the prevention 
of PCa.
Isoflavones
Isoflavones, a subclass of the flavonoids, are plant-derived 
compounds with weak estrogenic activity and therefore 
classified as phytoestrogens. Phytoestrogens have been sug-
gested to have a preventive effect against various cancers.17 
Soy foods are a rich source of isoflavones. Isoflavone intake 
in Asian countries is approximately 50 mg daily, which is 
about ten times higher than intake in western countries.18 The 
main isoflavones found in most soy products are genistein, 
daidzein, and glycitein. In vitro genistein and daidzein inhibit 
the growth of PCa cells19,20 and cause apoptosis.21,22 The 
mechanism of action of the isoflavones in soy products is 
not entirely clear. The biphasic bioactivity of genistein with 
low doses promoting cell growth and higher doses inhibiting 
growth requires caution in determining therapeutic doses 
of genistein alone or in combination with other therapies. 
Further investigation is warranted.23 In addition to epide-
miologic data, experimental studies in vitro and in vivo have 
also demonstrated protective effects of isoflavones against 
PCa development. Among these effects, isoflavones possess 
weak estrogen activity, inhibit tyrosine protein kinases, block 
angiogenesis, and reduce serum testosterone levels.24,25 They 
also inhibit 5 alpha-reductase, an enzyme that metabolizes 
testosterone to dihydrotestosterone.26 Isoflavones are further 
metabolized in humans to many different intermediates, such 
as equol, perhaps the best-studied metabolite of daidzein. 
Equol is ten times more potent than daidzein in retarding 
PCa growth.27
A cross-national study found that in the 42 countries 
for which there were appropriate data, soy products were 
significantly protective for PCa.28 Several studies show that 
dose-dependent serum isoflavone levels are associated with 
a decreased risk for PCa.29–32 A case-control study includ-
ing 200 patients and 200 age-matched controls evaluated 
the effects of isoflavones, fatty acids, vitamins, and miner-
als in the Japanese diet on PCa risk. They found that the 
isoflavones may be an effective dietary protective factor 
against PCa in   Japanese men. The odds ratio for the highest 
quartile ($89.9 mg/day) compared with the lowest quartile 
(,30.5 mg/day) of isoflavone intake was 0.42 (95% CI: 
0.24–0.72, P , 0.01).31 Kurahashi et al (2007) investigated 
the association between isoflavone intake and risk of PCa in 
a prospective study of Japanese men ages 45 to 75 years who 
generally consume large amounts of soy. During follow-up 
from 1995–2004, 307 men were newly diagnosed with PCa, of 
which 74 cases were advanced, 220 cases were organ localized, 
and 13 cases were of an undetermined stage. Men with the 
highest intake of isoflavones (as genistein $32.8 mg/day) had 
a decreased risk of PCa compared with those with the lowest 
intake of isoflavones (as genistein ,13.2 mg/day). The authors 
found that isoflavone consumption was associated with a 
dose-dependent decrease in the risk of localized PCa, with 
relative risks for men aged $ 60 years in the highest quartile 
of genistein, daidzein, and soy food consumption compared 
with the lowest of 0.52 (95% CI: 0.30–0.90, Ptrend = 0.03), 
0.50 (95% CI: 0.28–0.88, Ptrend = 0.04), and 0.52 (95% CI: 
0.29–0.90, Ptrend = 0.01), respectively. In con  trast, isoflavone 
consumption tended to be associated with an increased risk 
of advanced PCa.32 One mechanism of PCa risk reduction by 
isoflavones seems to involve estrogen receptor β in prostate 
tissue.33 Cancer with higher metastatic potential is correlated 
with the complete or partial loss of the expression of estrogen 
receptor β.34,35 Methodologic strengths of the study are the 
prospective design which reduces the probability of recall bias 
that is inherent to case-control studies, the fact that isoflavone 
intake was evaluated using a validated questionnaire and 
the large variation in isoflavone   consumption.32 Travis et al 
have examined plasma concentrations of phytoestrogens in 
relation to risk for subsequent PCa in a case-control study 
nested in the European Prospective Investigation into   Cancer 
and Nutrition (EPIC). Higher plasma concentrations of 
genistein were associated with lower risk of PCa: RR among 
men in the highest vs the lowest fifth, 0.71 (95% CI: 0.53–0.96, 
Ptrend = 0.03). No statistically   significant   associations were Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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observed for circulating concentrations of daidzein, equol, 
enterolactone, or enterodiol in relation to overall risk for 
prostate cancer.36
A nested case-control study conducted as part of the large 
Japan Public Health Center (JPHC)-based prospective cohort 
study investigated the effect of isoflavones as measured in 
plasma on subsequent PCa. This study is the first large study 
to investigate the association between plasma isoflavones 
and PCa to identify preventive effects of plasma isoflavones 
on localized PCa. In total, 20 newly diagnosed PCa were 
identified. Two matched controls for each case were selected 
from the cohort. They found that high plasma genistein (odds 
ratio (OR): 0.54, 95% CI: 0.29–1.01, Ptrend = 0.03 for high-
est vs lowest group) and equol levels (OR: 0.43, 95% CI: 
0.22–0.82, Ptrend = 0.02, for highest vs lowest group) were 
associated with a decreased risk of localized PCa, with dose 
dependency. These findings suggest that plasma isoflavone 
levels may be protective against the development of local-
ized PCa. Plasma isoflavone levels were not statistically 
significantly associated with the risk of advanced PCa.37 
A prospective study reported a decrease in PSA levels and 
lowered incidence of progression to PCa in men with isolated 
HGPIN in response to a 6-month supplementation with two 
tablets of Prevalon® (Madaus, Köln, Germany) per day. One 
tablet consists of 100 µg selenium, 30 mg vitamin E, and 
50 mg soy isoflavonoids (21 mg genistin, 17.6 mg daidzin, 
and 11.4 mg glycitin). The PCa risk throughout the study 
period was 25% in the group with a stable or declining 
PSA level from baseline and 52.2% (n = 48, 67.6%) in the 
group with a rising PSA level from baseline (n = 23, 32.4%) 
(P = 0.0458).38 Others have reported less PCa detection after 
6 months of soy supplementation among high-risk patients.39 
Other case-controlled studies support the idea of a protective 
effect of soy products for PCa,40,41 possibly because the pros-
tatic isoflavone concentrations exceed the plasma levels after 
dietary supplementation.42–44 Levels of approximately 1 µg 
isoflavone concentrations in the blood are regarded to be the 
highest achievable levels through intake of food.45 However, 
levels of isoflavone concentrations in prostatic tissue seem 
to be more relevant than blood levels. In a double-blind, 
randomized, placebo-controlled study, the administration of 
82 mg isoflavones per day (27.2 mg/tablet of total isoflavone, 
aglycone equivalent, contains 10.6 mg genistein, 13.3 mg 
daidzein, and 3.2 mg glycitein) for 2 weeks in 19 men prior 
to radical prostatectomy (RP), resulted in a total isoflavone 
serum level of 0.7 µmol/L and a corresponding prostate tissue 
level of 2.3 µmol/L. Thus, prostate tissue is able to accu-
mulate isoflavones to potentially anticarcinogenic levels.41 
Nevertheless, several studies have shown negligible benefits 
in men who received soy supplementation.46–48
Possible reasons for these inconsistent findings are dif-
ferences in study design, sample size, doses administered, 
and/or isoflavone concentrations achieved in the body.49 The 
results of a very recent meta-analysis of the now available 14 
epidemiological studies (8 on isoflavones) suggest that soy 
and isoflavone consumption is associated with a decreased 
risk of PCa. Soy food consumption was associated with a 
reduction in PCa risk of approximately 26% in men when 
the highest reported intake was compared with the lowest 
reported intake. The protective effect is related to the type 
and quantity of soy food consumed. The analysis on soy 
intake yielded a combined relative risk/odds ratio (RR/OR) 
of 0.74 (95% CI: 0.63–0.89, P = 0.01). The analysis of studies 
on nonfermented soy foods yielded a RR/OR of 0.70 (95% 
CI: 0.56–0.88, P = 0.01) and those on fermented soy foods 
yielded a combined RR/OR of 1.02 (95% CI: 0.73–1.42; 
P = 0.92). The analysis of studies on isoflavones yielded a 
combined RR/OR of 0.88 (95% CI: 0.76–1.02, P = 0.09). 
Further separate analyses showed a combined RR/OR of 
0.52 (95% CI: 0.34–0.81, P = 0.01) from studies with Asian 
populations and 0.99 (95% CI: 0.85–1.16, P = 0.91) from 
studies with western populations. Well-designed studies on 
fermented and nonfermented soy foods in PCa etiology and 
prevention are required.50
To date, although there exists overwhelming data on 
epidemiologic studies, case control studies, and in vitro/vivo 
data that soy isoflavone may be a promising chemopreventive 
agent against PCA, there have been no published prospective 
randomized clinical studies with sufficient statistical power 
to assess whether isoflavone supplementation can reduce 
PCa development or delay PCa progression. Shortcomings 
for many studies published to date are small patient numbers, 
lack of randomization, short-term isoflavone administration, 
and possibly insufficient doses.51 Current ongoing clinical tri-
als may help us understand the role of soy in the   prevention 
of PCa.
Lycopene
Lycopene is a carotenoid without vitamin A activity that 
gives the red color to tomatoes and tomato-derived products. 
It is also available in other red fruits and vegetables such 
as red carrots, watermelons, pink grapefruit, and papayas. 
It possesses potent antioxidant activity and appears to have 
anticancer properties.52
An update of the results of the Health Professionals 
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Dovepress 
Dovepress
96
Poppel and Tombal
frequent consumption of tomato products or lycopene is 
associated with a lower risk of PCa. The results were based 
on multiple dietary assessments using semiquantitative food-
frequency questionnaires from 1986 to 1998 and on 2481 
cases of PCa. High lycopene intake was associated with a 
reduced risk of PCa (RR for high vs low quintiles is 0.84 
(95% CI: 0.73–0.96; Ptrend = 0.003). Intake of tomato sauce, 
the primary source of bioavailable lycopene, was associated 
with an even greater PCa risk reduction: RR for more than 
two servings/week vs less than one serving/month is 0.77 
(95% CI: 0.66–0.90, Ptrend = , 0.001). These results suggest 
that lycopene may have a role in the prevention of PCa.53 
A large nested case-control study within the prospective 
Health Professionals Follow-up Study found a statistically 
significant inverse association between higher plasma lyco-
pene concentrations and lower risk of PCa, restricted to par-
ticipants of 65 years or older (OR: 0.47, 95% CI: 0.23–0.98) 
at time of blood donation and those without a family history 
of PCa (OR: 0.43, 95% CI: 0.26–0.89).54 A Phase II clinical 
study showed that 30 mg of oral lycopene supplementation 
for 3 weeks prior to RP reduced tumor size and plasma PSA 
level in localized PCa. Twelve of fifteen (84%) men in the 
lycopene group and five of eleven (45%) men in the control 
group had tumors ,4 mL in size (P = 0.22). Plasma PSA 
levels decreased by 18% in the intervention group, whereas 
they increased by 14% in the control group (P = 0.25).55 
Chen et al (2001)56 and Ansari and Gupta (2003)57 also 
reported a decrease in PSA level with lycopene supplementa-
tion in patients with PCa.
A meta-analysis of 11 case-control studies and 10 cohort 
studies or nested case-control studies showed that tomato 
products and lycopene may play a role in the prevention of 
PCa although the effect is modest and limited to high amounts 
of tomato products. The main findings were that, compared 
with nonfrequent users of tomato product (1st quartile of 
intake) the RR of PCa among consumers of high amounts 
of raw tomato (5th quintile of intake) was 0.89 (95% CI: 
0.80–1.00). For a high intake of cooked tomato products, the 
corresponding RR was 0.81 (95% CI: 0.71–0.92). The RR 
of PCa related to an intake of one serving/day of raw tomato 
(200 g) was 0.97 (95% CI: 0.85–1.10) for the case-control 
studies and 0.78 (95% CI: 0.66–0.92) for cohort studies. 
For serum- or plasma-based studies, the corresponding RRs 
were 0.74 (95% CI: 0.59–0.92) for all studies, 0.55 (95% 
CI: 0.32–0.94) for case-control studies, and 0.78 (95% CI: 
0.61–1.00) for cohort studies.58 In a Phase II study, subjects 
with PCa were randomly assigned to receive a tomato capsule 
extract containing 15 mg lycopene alone (n = 38) or together 
with a capsule containing 40 mg of a soy isoflavone mixture 
(n = 33) twice daily orally for a maximum of 6 months. 
Thirty-five of 37 (95%) evaluable patients in the lycopene 
group and 22 of 33 (67%) evaluable patients in the lycopene 
plus soy isoflavone group achieved stable disease described 
as stabilization in serum PSA level. Future studies should fur-
ther investigate the potential reactions between lycopene and 
soy isoflavones in PCa because both compounds are found 
in the diet and they are often taken together as   supplements 
by PCa patients.48
Apparently lycopene is not only a promising component 
for chemoprevention of PCa, but can also play a possible 
beneficial role in patients diagnosed with benign prostate 
hyperplasia (BPH). In a pilot study, a total of 40 patients 
with histologically proven BPH were randomized to receive 
either lycopene (15 mg/day) or placebo for 6 months. The 
6-month lycopene supplementation at a dose of 15 mg/day 
decreased PSA levels in men (P , 0.05), inhibited disease 
progression, and improved the symptoms in BPH patients 
(P , 0.01) whereas there was no change in the placebo 
group.59 Indications for potential suppressive effects of 
lycopene on disease progression in BPH exist from a pre-
vious pilot study in PCa patients showing an increase in 
apoptotic cell death by lycopene in cancer-free BPH tissue.60 
  Moreover, analysis by experts of the World Cancer Research 
Fund shows that there is a sufficient body of evidence for 
the protective effect of lycopene-containing foods, especially 
tomatoes and their derivates, on PCa. This claim is based on 
five cohort studies and nine case control studies which inves-
tigated tomatoes; three cohort studies and 14 case-control 
studies investigated dietary lycopene; whilst six cohort 
studies and two case control studies investigated serum or 
plasma lycopene. Most of the studies decreased risk with 
increased intake (www.dietandcancerreport.org).61 A large 
nested case-control study in the prostate, lung, colorectal, 
and ovarian cancer screening study including 692 PCa cases62 
and the recently published Prostate Cancer Prevention Trial13 
including 9,559 participants found no correlation between 
lycopene and the incidence of PCa. Because chemopreven-
tion is probably most effective in the early stages of PCa, 
the next study carried out with lycopene in the treatment of 
HGPIN is worth mentioning. A randomized, double-blind, 
placebo-controlled, one-year study of lycopene 4 mg twice 
a day has been conducted in 40 patients with HGPIN at 
transurethral resection of the prostate. PCa reduction after 
one year of treatment was 66%. Lycopene was considered an 
effective chemopreventive agent in the treatment of HGPIN, 
with no toxicity and good tolerability.63Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Despite this randomized, double-blind study with 
  lycopene, which proved to be an effective agent in the treat-
ment of HGPIN, larger randomized controlled trials are 
required in well-defined patient sub-groups.
Polyphenols
Polyphenols are the largest group of constituents found in 
tea. Green tea contains catechins, a category of water-soluble 
polyphenolic substances. The four principal catechins are 
(-)-  epicatechin (EC), (-)-epicatechin-3-gallate (ECG), 
 ( -)-  epigallocatechin (EGC), and (-)-epigallocatechin-3-gallate 
(EGCG).64 EGCG, found in the highest concentration in green 
tea, is the most studied and most active of all green tea catechins 
(GTC) for the inhibition of oncogenesis and reduction of oxida-
tive stress. The mode of action of polyphenols has not yet been 
fully determined. Several epidemiologic studies have focused 
on the lower incidence of PCa in Asian populations where green 
tea is consumed regularly as compared with western popula-
tions, suggesting that green tea is protective against PCa.
Previous clinical investigations in healthy men have 
shown when a standardized green tea extract (eg, Polyphe-
non E) is used, the product is safe and tolerable.65 In 2006, 
a randomized, double-blind, placebo-controlled study was 
performed as a one-year proof-of-principle trial to assess the 
safety and efficacy of GTC capsules for the chemoprevention 
of PCa in HGPIN volunteers.66 Sixty patients were random-
ized to 600 mg GTCs per day (ie, three 200 mg capsules) or 
placebo. Each capsule contains 5.5% EGC, 12.2% EC, 51.9% 
EGCG, 6.1% ECG, 75.7% total GTCs, and ,1% caffeine. 
After one year, only 1 of 30 GTC-treated men (incidence 
approximately 3%) was found to have PCa compared to 9 of 
30 placebo-treated men (incidence, 30%). Altogether, these 
data suggest that a 90% reduction in developing PCa can be 
safely obtained by GTCs administration in men with HGPIN. 
This is the first study showing that GTCs have potent in vivo 
chemoprevention activity for human PCa. GTC treatment did 
not have a significant effect on PSA values throughout the 
study. In any case, the mean value of total PSA was always 
lower in patients randomized to GTCs than in patients on 
placebo. Secondary observations were changes in lower 
urinary tract symptoms (LUTS) as assessed by International 
Prostate Symptom Score (IPSS) and Quality of Life scores 
(QoL). IPSS and QoL scores of GTC-treated men with coex-
istent benign prostate hyperplasia (BPH) improved, reaching 
statistical significance in the case of IPSS. No significant side 
or adverse effects have been reported.66 A 2-year follow-up 
was performed in a subset of patients and showed that GTCs 
had a long-lasting effect on PCa prevention.67
A larger, randomized, double-blind, placebo-controlled 
study in 272 HGPIN patients in the United States will assess 
the rate of progression to PCa after treatment with either 
200 mg EGCG as Polyphenon E twice daily (ie, 400 mg 
EGCG/day) or placebo over a 1 year period   (ClinicalTrials.
gov Identifier NCT00596011). A recently published, Phase II, 
open-label, single-arm, two-stage clinical trial determined the 
effects of short-term supplementation with the standardized 
green tea extract Polyphenon E on serum biomarkers in 
26 patients with PCa. Daily doses of the standardized green 
tea extract administered during the interval between prostate 
biopsy and RP until time of RP contained 800 mg of EGCG 
and lesser amounts of EC, EGC, and ECG (a total of 1.3 g 
of tea polyphenols). The results showed a significant reduc-
tion in serum levels of PSA, hepatocyte growth factor, and 
vascular endothelial growth factor in men with PCa, with 
no elevation of liver enzymes.68 Results with green tea poly-
phenols for PCa chemoprevention are encouraging. Larger 
clinical trials of men at risk of PCa or with early stage PCa 
are needed to better assess the role of green tea polyphenols 
in the prevention of PCa.
Calcium
Several large case-control and cohort studies have dem-
onstrated that a high calcium intake from foods and/or 
supplements is associated with increased PCa risk.69–74 
Giovannucci et al examined calcium intake in relation to 
prostate cancer risk using data from the Health Professionals 
Follow-up Study, a prospective cohort study of 47,750 male 
health professionals with no history of cancer other than 
nonmelanoma skin cancer at baseline. For high-grade PCa 
(Gleason score $ 7), an association was observed for high 
versus low calcium intake (RR, 1.89; 95% CI: 1.32–2.71; 
Ptrend = 0.005), but a nonsignificant, inverse association was 
observed for organ-confined, low-grade PCa (RR, 0.79; 
95% CI:   0.50–1.25; Ptrend = 0.09). Very high calcium intakes 
(.1500 mg/day) were associated with a higher risk of 
advanced and fatal PCa but not with well-differentiated, 
organ-confined cancers.72 Similarly, Allen et al have exam-
ined the consumption of calcium in relation to the risk of 
PCa among 142.251 men in the European Prospective Inves-
tigation into Cancer and Nutrition (EPIC) Study. After an 
average of 8.7 years of follow-up, there were 2727 incident 
cases of PCa, of which 1131 were known to be localized and 
541 advanced-stage disease. Total dietary calcium intake 
and calcium intake from dairy foods were associated with 
an increased risk of PCa (hazard ratio for the highest vs 
the lowest fifth of intake were 1.17, 95% CI: 1.00–1.35 Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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for total dietary calcium and 1.18, 95% CI: 1.03–1.36 for 
dairy calcium). Calcium intake from nondairy foods was 
not associated with risk for PCa.71 This is in contrast with 
the finding of the Prostate Cancer Preventive Trial where 
calcium intake was positively associated with risk of low-
grade cancer but inversely associated with risk of high-
grade cancer (for quartile 4 vs quartile 1, odds ratios were 
1.27 (95% CI: 1.02–1.57) and 0.43 (95% CI: 0.21–0.89), 
respectively). No evidence has been found that very high 
dietary calcium intakes (.1400 mg/day) were associated 
with increased risk of high-grade PCa.13 This inconsistency 
in findings may require further investigation.
Resveratrol
Resveratrol (3,5,4′-trihydroxystilbene), a natural stilbenoid 
present in red wine, grapes, berries, peanuts, and dietary 
supplements as well as polyhydroxy analogs of resvera-
trol have potential cancer chemopreventive properties. 
It has   sensitization/enhancing activities against tumor 
cells when used in combination with standard cancer 
  chemotherapeutics.75 Recent findings strongly suggest that 
suppressor of cytokine signaling (SOCS-3), an antiapoptotic 
molecule that is upregulated in PCa is one of the proteins 
that influence the ability of resveratrol and tumor necrosis 
factor (TNF)-related apoptosis-inducing ligand (TRAIL) to 
cause programmed cell death in PCa.76 Future studies should 
concentrate on the determination of molecular mechanisms 
of chemosensitization, efficacy of resveratrol combinations 
by clinically relevant in vivo studies, and demonstration of 
safety and effectiveness of combinations in humans.77
who should receive  
chemoprevention for PCa?
For high-risk patients, chemopreventive agents may be dis-
cussed, as the risk of PCa may justify the cost and potential 
side effects of these agents. It also seems reasonable to 
believe that chemoprevention strategies are more effec-
tive in high-risk groups. Nevertheless, the identification of 
high-risk groups is at this moment not easy. Patients with 
isolated HGPIN on prostate biopsies constitute a unique and 
well-demarcated risk group for PCa. Prognostic, randomized 
data on chemopreventive strategies in HGPIN are scarce, but 
seem promising. Other high-risk groups include those above 
40 years of age, elevated PSA levels, rapid PSA velocity, 
sub-Saharan African ethnicity, a family history of PCa or 
with specific genes, or obese men with insulin resistance and 
those who would benefit from early diagnosis and treatment 
with at least 10–15 years of life expectancy.
Conclusions and future perspectives
The concept of primary prevention is relatively new in the 
topic of prostate cancer and the effect of chemopreventive 
agents such as soy isoflavones, lycopene, and green tea poly-
phenols show encouraging results, although larger Phase III 
studies are needed. Some studies investigating selenium, 
alpha-tocopherol, and lycopene in the prevention of PCa 
show negative results. Differences in study design, sample 
size, dose administered, and/or concentrations achieved in 
the body may be the reason for these inconsistencies. The 
impact of calcium and resveratrol on PCa risk requires 
further investigation. Today, chemopreventive agents may 
be appropriate for high-risk patients such as patients with 
isolated HGPIN, elevated PSA, and negative biopsy, but are 
not appropriate for routine recommendation. Future research 
should focus on determining the target population for PCa 
chemoprevention. Large prospective randomized studies are 
required to define the benefits of chemopreventive agents 
for PCa. Some of these studies are ongoing and results are 
eagerly awaited. Combinations of chemopreventive agents 
for PCa should be carefully investigated because mechanisms 
of action may be additive or synergistic.
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